Phenotypes Associated with This Genotype

Genotype
MGI:5435674

• Allelic Composition: Fktn^tm1Kcam/Fktn^tm1Kcam; Tg(CAG-cre/Esr1*)5Amc/?
• Genetic Background: involves: 129S/SvEv * C57BL/6 * CBA

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

muscle

dystrophic muscle ( J:187144 )

• iliopsoas muscle from mice treated with tamoxifen show indications of dystrophic disease

• variations in fiber size

• necrosis

• increase in centrally nucleated fibers

homeostasis/metabolism

increased circulating creatine kinase level ( J:187144 )

• levels begin to rise at 14 weeks of age and are significantly elevated at 16-20 weeks after tamoxifen treatment at 10 weeks of age

growth/size/body

growth/size/body region phenotype ( J:187144 )

N • normal body weight at 4- 20 weeks of age after tamoxifen treatment

behavior/neurological

behavior/neurological phenotype ( J:187144 )

N • normal forelimb grip strength at 4-20 weeks of age after tampxifen treatment

N • normal open field activity at 4-20 weeks of age after tampxifen treatment

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
Fukuyama congenital muscular dystrophy		DOID:0050559	OMIM:253800	J:187144